| Literature DB >> 33270986 |
Katerina Placek1, Michael Benatar2, Joanne Wuu2, Evadnie Rampersaud3, Laura Hennessy1, Vivianna M Van Deerlin4, Murray Grossman1, David J Irwin1, Lauren Elman1, Leo McCluskey1, Colin Quinn1, Volkan Granit2, Jeffrey M Statland5, Ted M Burns6, John Ravits7, Andrea Swenson8, Jon Katz9, Erik P Pioro10, Carlayne Jackson11, James Caress12, Yuen So13, Samuel Maiser14, David Walk14, Edward B Lee4, John Q Trojanowski4, Philip Cook15, James Gee15, Jin Sha16,17, Adam C Naj4,16,17, Rosa Rademakers18, Wenan Chen3, Gang Wu3, J Paul Taylor3,19, Corey T McMillan1.
Abstract
Amyotrophic lateral sclerosis (ALS) is a multi-system disease characterized primarily by progressive muscle weakness. Cognitive dysfunction is commonly observed in patients; however, factors influencing risk for cognitive dysfunction remain elusive. Using sparse canonical correlation analysis (sCCA), an unsupervised machine-learning technique, we observed that single nucleotide polymorphisms collectively associate with baseline cognitive performance in a large ALS patient cohort (N = 327) from the multicenter Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium. We demonstrate that a polygenic risk score derived using sCCA relates to longitudinal cognitive decline in the same cohort and also to in vivo cortical thinning in the orbital frontal cortex, anterior cingulate cortex, lateral temporal cortex, premotor cortex, and hippocampus (N = 90) as well as post-mortem motor cortical neuronal loss (N = 87) in independent ALS cohorts from the University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Our findings suggest that common genetic polymorphisms may exert a polygenic contribution to the risk of cortical disease vulnerability and cognitive dysfunction in ALS.Entities:
Keywords: amyotrophic lateral sclerosis; cognition; frontotemporal dementia; machine learning; polygenic score
Mesh:
Year: 2020 PMID: 33270986 PMCID: PMC7799365 DOI: 10.15252/emmm.202012595
Source DB: PubMed Journal: EMBO Mol Med ISSN: 1757-4676 Impact factor: 14.260